OSE Immunotherapeutics Presents First Preclinical Efficacy Data on Anti-IL-7 Receptor Antagonist OSE-127 in Acute Lymphoblastic Leukemia
At the 2021 American Society of Hematology (ASH) Annual Meeting Regulatory News: OSE Immunotherapeutics SA (Paris:OSE) (ISIN: FR0012127173; Mnemo: OSE) presented the first preclinical data on
United States Sachsen Anhalt Denis Schewe Guillaume Van Renterghem Lifesci Thomas Guillot Florence Portejoie
Source: finanznachrichten.de